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Highlights 
• Synthesis of polyfluoroaromatic Stavudine (d4T) ProTides. 
• Anti-retroviral activity against two strains; HIV-1, (IIIB) and HIV-2, (ROD) in MT4 cell line. 
• Evaluation of anti-HIV activity against wild type (C8166) as well as thymidine kinase 
deficient (C8166-TK-) cells.  
• Nanomolar antiviral activity of novel ProTide 5d containing 3-SF5 aromatic ring; IC50 = 30 
nM, HIV-1 and IC50 = 36 nM, HIV-2, more than tenfold that of d4T. 
• High selectivity index of 5d, SI = 1753 (HIV-1) and 1461 (HIV-2) twice that of d4T. 
• Enzymatic activation of 5d is monitored by 31P and 19F NMR. 
• Polyfluoroaromatic ProTides have high in vitro aqueous solubility. 
Human Immunodeficiency Virus (HIV) damages the immune system and leads to the life-
threatening acquired immunodeficiency syndrome (AIDS). Despite the advances in the field 
of antiretroviral treatment, HIV remains a major public health challenge.  
Nucleosides represent a prominent chemotherapeutic class for treating viral infections, 
however their cellular uptake, kinase-mediated activation and catabolism are limiting factors. 
Herein, we report the synthesis and in vitro evaluation of stavudine (d4T) ProTides containing 
polyfluorinated aryl groups against two strains; HIV-1 (strain IIIB) and HIV-2 (strain ROD). 
ProTide 5d containing a meta-substituted pentafluorosulfanyl (3-SF5) aryl group17 showed 
superior antiviral activity over the parent d4T and the non-fluorinated analogue 5a. ProTide 
5d has low nanomolar antiviral activity; (IC50 = 30 nM, HIV-1) and (IC50 = 36 nM, HIV-2) which 
is over tenfold more potent than d4T. Interestingly, ProTide 5d showed significantly high 
selectivity indices (SI) = 1753 (HIV-1) and 1461 (HIV-2) which is more than twice that of the 
d4T. All ProTides were screened in wild type as well as thymidine kinase deficient (TK-) cells. 
Enzymatic activation of ProTide 5d using carboxypeptidase Y enzyme and monitored using 
both 31P and 19F NMR is presented. 
Human Immunodeficiency Virus (HIV) is a retrovirus, of the family Retroviridae, which is 
characterised by the presence of the reverse transcriptase (RT) enzyme1. HIV damages the 
immune system and causes higher susceptibility to life-threatening opportunistic infections, 
known as acquired immunodeficiency syndrome (AIDS). Many advances have been made in 
antiretroviral therapy that have turned AIDS into a chronic condition rather than a fatal 
illness2. However, HIV remains a major public health challenge because of the high mutation 
rate of HIV-RT, the adverse side effects of the antiretroviral treatment and the poor patient 
compliance in clinical applications3. Nucleoside / nucleotide reverse-transcriptase inhibitors 
(NRTIs/NtRTIs) represent the first major class of antiretroviral drugs developed 4.  
Nucleoside analogues are a well-established class of antiviral and anticancer therapeutic 
agents. Enzymatic phosphorylation is required to convert the nucleoside analogues to the 5’-
monophosphates and subsequently to the triphosphate derivatives 5-7. Often the three-step 
intracellular phosphorylation is inefficient and rate-limited by the initial 
monophosphorylation step. Further, reduced expression of nucleoside kinases leads to 
resistance to the nucleoside analogue treatment 5,6. Therefore, notable efforts have focused 
on the delivery of monophosphate prodrugs that are capable of masking the negative charge 
of the phosphate group. The monophosphate phosphoramidate pro-nucleotides, known as 
ProTides, represent a successful strategy for bypassing the dependence on active transport 
and nucleoside kinase-mediated activation 8,9. This is demonstrated clinically by sofosbuvir 
(anti-HCV, FDA approved) 6 and acelarin (anticancer, Phase III) 9, shown in Figure 1. 
 
Figure 1: Chemical structures of sofosbuvir (anti-HCV, FDA approved), acelarin (anticancer, Phase III) ProTides 
and stavudine (d4T) nucleoside. 
 
Stavudine (2’,3’-didehydro-2’,3’-dideoxythymidine, d4T) is an approved antiviral nucleoside 
for the prevention or treatment of HIV infection, usually as part of antiretroviral combination 
therapy10. In an attempt to overcome the first intracellular thymidine kinase-directed 
phosphorylation step of d4T, phosphoramidate derivatives were prepared and evaluated 
against HIV11. 
Generally, introduction of fluorinated substituents can provide a unique combination of 
electronegativity, size and lipophilicity and can also greatly affect physicochemical 
properties12-14. In this work we synthesised phosphoramidate derivatives of d4T (Scheme 1) 
and compared the effect of introducing different polyfluorinated variants of the aromatic ring 
(4-CF3 / 3-CF3 / 3-SF5) and investigated whether the lipophilic and electronegative properties 
of the corresponding ProTides would affect their anti-HIV activity and toxicity profiles 
compared to the non-fluorinated ProTide.  
Stavudine (d4T) ProTides were prepared using previously described phosphorochloridate 
chemistry15. The phenyl phosphorodichloridates 2a-d were prepared by the reaction of 
substituted phenols 1a-d with POCl3. The subsequent reaction with methyl alanine 3 to form 
the corresponding phosphorochloridates 4a-d was monitored by 31P NMR. Next the 
arylaminoacyl phosphorochloridates 4a-d were reacted with d4T in the presence of t-BuMgCl 
as a hindered base (Scheme 1). Stirring for 24h at ambient temperature generated the crude 
ProTides 5a-d that were purified by column chromatography to provide the characteristic low 
to moderate yields associated with ProTide chemistry, for the final products (20–34%)16. Each 
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of the phosphoramidates was generated as a pair of diastereoisomers at the phosphorus 
centre, in a roughly 1:1 ratio, as revealed by the two closely spaced peaks in the 31P NMR 
spectrum (see Supporting Information). It is worth mentioning that due to the instability of 
the intermediates it was not feasible to prepare the 4-SF5 analogue. 
 
Scheme 1. Synthesis of d4T phosphoramidate analogues; Reagents and conditions: i) Et3N, anhydrous Et2O, -78 
°C to rt, 2 h, ii) Et3N, anhydrous DCM, -78 °C, 3 h, iii) t-BuMgCl, anhydrous THF, -78 °C to rt, 24 h.   
ProTides need to be metabolised to release the monophosphate form, which will then 
undergo further intracellular phosphorylation steps to generate di- and triphosphate active 
form. The proposed intracellular activation pathway of the most active ProTide 5d is 
described in Scheme 2, in accordance with previous literature15. Metabolic breakdown starts 
with the hydrolysis of the ProTide carboxylate ester, mediated by a carboxyesterase-type 
enzyme to form intermediate A, which is followed by a spontaneous cyclisation displacing the 
aryl moiety via an internal nucleophilic attack of the carboxylate residue on the phosphorus 
centre to yield intermediate B. In the third step, the unstable cyclic mixed anhydride is 
thought to be hydrolysed to release the intermediate C. The final step then involves a 
phosphoramidase-type enzyme, which would cleave off the amino acid to generate the 
corresponding monophosphate D, trapped within the cell due to the polar nature of the 
monophosphate.  
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Scheme 2. Proposed activation pathway of d4T ProTide 5d initiated by esterase or carboxypeptidase enzyme. 
To probe the activation process of ProTide 5d, Scheme 2, an enzymatic study using 
carboxypeptidase Y enzyme was carried out. ProTide 5d was incubated with 
carboxypeptidase Y to verify that the enzymatic cleavage of the ester motif is sufficient to 
initiate the activation process and generate intermediate C. Compound 5d was dissolved in 
acetone-d6 in the presence of Trizma buffer (pH 7.6), treated with carboxypeptidase Y and 
monitored by 31P NMR chemical shift changes over time, Figure 2. Two peaks at δ 3.61 and 
3.27 ppm in the blank spectrum recorded at 25 °C correspond to the diastereoisomers of the 
parent compound 5d. Within 7 mins of incubation with carboxypeptidase Y, a single peak at 
around δ 6 ppm started appearing, which is consistent with the single chemical shift expected 
for the formation of achiral intermediate C via the putative intermediate B. The peak height 
increased over time suggesting the accumulation of a stable product. The spectra recorded 
during the enzymatic reaction suggest that within 2 h of the start of the assay 5d was almost 
fully converted into metabolite C.  
 
Figure 2. 31P NMR spectra of d4T ProTide 5d over time after carboxypeptidase Y treatment showing the signals 
of the metabolite C over time.  
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Moreover, due to the presence of the 3-SF5 group in 5d, we considered that the activation 
process of ProTide 5d using carboxypeptidase Y enzyme can be also monitored using 19F NMR 
chemical shift changes over time, Figure 3. The appearance of two doublet peaks at δ 62.15 
and 62.48 ppm in the blank spectrum corresponds to the diastereoisomers of the parent 
compound 5d. The new doublet signal appearing at δ 61.86 and 62.21 (corresponding to the 
four fluorine atoms of the SF5 group) indicating the release of 3-SF5 phenol (1d). 
 
Figure 3. 19F NMR spectra of ProTide 5d over time after carboxypeptidase Y treatment showing the signals of 
the metabolites over time. 
 
Both 31P NMR and 19F NMR monitoring experiments, Figure 2 and 3, indicate that ProTide 5d 
activation is initiated by the carboxpeptidase enzyme Y and that after 1.25h of incubation 
most of the ProTide is metabolised. Quantification of intracellular drug levels would be the 
focus of future investigation. 
Nucleoside reverse transcriptase inhibitors (NRTIs) and nucleotide analogue reverse-
transcriptase inhibitors (NtRTIs) act as chain terminators for both viral and host DNA 
synthesis4. The former describes their antiviral activity, while the latter describes their drug 
toxicity/side effects. Hence, d4T ProTides 5a-d were screened for both antiviral activity and 
cytotoxicity.  
The antiviral activity profile of compounds 5a-d was evaluated in MT4 cells against two HIV 
strains; HIV-1 (IIIB) and HIV-2 (ROD) in parallel with stavudine (d4T) as a positive control. The 
biological results are expressed as IC50, CC50 and SI (selectivity index; CC50/IC50 ratio). 
All ProTides showed markedly enhanced antiviral activity compared to the parent d4T except 
the non-fluorinated ProTide 5a which is slightly more potent than d4T. The best activity was 
F5S
OH
observed across both HIV types in ProTide 5d with the meta-pentafluorosulfanyl (3-SF5) 
substituent attached to its aromatic ring. ProTide 5d has low nanomolar antiviral activity; (IC50 
= 30 nM, HIV-1) and (IC50 = 36 nM, HIV-2) which is over tenfold more potent than d4T, Table 
1. Additionally, ProTide 5d showed significantly high selectivity indices (SI) = 1753 (HIV-1) and 
1461 (HIV-2) which is more than twice that of the d4T. This could be attributed to its enhanced 
lipophilic and/or electronegative properties imparted by the presence of five fluorine atoms. 
Also, the position of the CF3 substituent in the phenyl ring of 5b and 5c has little influence on 
the anti-HIV activity but more effect on the toxicity profile which was in favour of the meta-
CF3 (5c) over the para-CF3 (5b) as observed in the selectivity index values; SI (5c) = 1612 (HIV-
1) and 1349 (HIV-2) compared to SI (5b) = 1159 (HIV-1) and 921 (HIV-2), Table 1.  
  HIV-1 (IIIB) HIV-2 (ROD) 
comp IC50 (µM) CC50 (µM) SI IC50 (µM) CC50 (µM) SI 
d4T 0.40±0.09 313±7 782 0.45±0.09 313±7 695 
5a 0.21±0.09 251±7 1195 0.27±0.11 251±7 930 
5b 0.037±0.002 42.9±12.6 1159 0.047±0.022 42.9±12.6 912 
5c 0.041±0.006 66.1±24.8 1612 0.049±0.017 66.1±24.8 1349 
5d 0.030±0.012 52.6±4.9 1753 0.036±0.020 52.6±4.9 1461 
Table 1. Anti-HIV-1 and 2 activity and cytotoxicity of stavudine (d4T) and ProTide analogues 5a-d.  
 
 
Further, we tested our compounds in the C8166 cell line and a variant thymidine kinase 
deficient variant (C8166-TK-) to probe the effect of TK deficiency on the activity of the test 
compounds and the degree to which the ProTides could bypass this dependence.  
 As shown in Table 2, the fluorinated ProTides 5b-d displayed greatly enhanced antiviral 
potency than the non-fluorinated analogue 5a or the parent d4T across. ProTide 5b (4-CF3) 
has around 180-fold higher activity than d4T, while ProTide 5d (3-SF5) is around 75-fold more 
active than d4T. It is interesting to observe that compounds 5a, 5b and 5d can retain their 
activity in TK deficient cells while d4T has completely lost its activity. While ProTide 5c (IC50 = 
0.039 µM) shows better activity than 5a (IC50 = 0.30 µM) and d4T (IC50 = 4.06 µM), it is not 
active in TK- cells. This is most probably because 5c uptake is enhanced but it falls back to its 
free nucleoside form and cannot be re-phosphorylated in these cells, Table 2.  
 
  HIV-1 (IIIB) 
ID IC50 WT (µM) IC50 TK- (µM) 
d4T 4.06±0.18 NA 
5a 0.30±0.04 0.32±0.15 
5b 0.022±0.006 0.075±0.000 
5c 0.039±0.007 NA 
5d 0.054±0.039 0.335±0.004 
 
Table 2. Antiviral activity of stavudine (d4T) and ProTide analogues 5a-d against HIV-1 strain IIIB in the C8166 
cell line and the thymidine kinase deficient (C8166-TK-) cell line. NA: not active 
 
Introduction of fluorine atoms into molecular structures increases their hydrophobicity. Thus, 
we investigated the in vitro turbidimetric aqueous solubility of the polyfluorinated ProTides 
5b-d using five concentrations (1, 3, 10, 30 and 100 μM) in phosphate buffered saline (PBS; 
pH 7.4) solution (1% DMSO), which were incubated at 37°C for 2 hr. The estimated 
precipitation range (lower and upper bound) and a mid-range value were calculated for 
compounds 5b-d. Nicardipine and pyrene were used as control compounds. The results show 
that ProTides with polyfluoroaromatic substituents 5b-d retain high aqueous solubility with 
estimated precipitation range 100 μM (lower bound) and >100 μM (upper bound), Table 3, 
confirming their potential advantage for intestinal absorption. 
 
Compound MW ClogPa 
Estimated Precipitation range (µM) Estimated 
solubility 
(µM) 
Lower 
bound 
Upper 
bound 
Calculated mid-range 
d4T 224.22 -0.4875 100 100 100  > 100 
5b 533.40 1.9788 100 100 100 > 100 
5c 533.40 1.9788 100 100 100 > 100 
5d 591.44 2.3288 100 100 100 > 100 
Nicardipine - - 10 30 20 10-30 
pyrene - - 3 10 6.5 3-10 
Table 3. Aqueous solubility of 5b-d versus control compounds (nicardipine and pyrene) in PBS (pH=7.4) 
buffered aqueous solution. aCalculated by PerkinElmer ChemDraw 16.0 software. 
 
In this study, a series of polyfluoroaromatic ProTides of d4T were synthesised. The antiviral 
activity was evaluated in vitro against the two HIV types; HIV-1 (strain IIIB) and HIV-2 (strain 
ROD). Our findings identified compound 5d featuring a meta-pentafluorosulfanyl (SF5) in its 
aromatic ring as promising lead. ProTide 5d has low nanomolar antiviral activity; (IC50 = 30 
nM, HIV-1) and (IC50 = 36 nM, HIV-2) which is over tenfold more potent than d4T. Moreover, 
5d has the best activity / toxicity profile with a selectivity index (SI) = 1753 (HIV-1) and 1461 
(HIV-2), which is more than twice that of the parent d4T (SI) = 782 (HIV-1) and 695 (HIV-2).  
Additionally, ProTides 5a, 5c and 5d retained some activity in the thymidine kinase deficient 
(C8166-TK-) cell line. Furthermore, the polyfluorinated ProTides 5b-d retained aqueous 
solubility comparable to that of the parent d4T. Considering the above findings, it is concluded 
that 5d represents a promising basis for further development of NtRTI anti-HIV therapies. 
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S1. Chemistry 
The anhydrous solvents and any other commercially available reagents were purchased from 
Sigma-Aldrich (U.K.) and used without further purification. Amino acid esters were purchased 
from Carbosynth (U.K.). Carboxypeptidase Y and buffers were purchased from Sigma-Aldrich 
(U.K.). All reactions were carried out under nitrogen atmosphere. Reactions were monitored 
with analytical TLC on silica gel 60-F254 precoated aluminium plates and visualised under UV 
(254 nm) and/or using 31P NMR spectra. Column chromatography was performed on silica gel 
(35-70 μM). Preparative TLC plates (20 cm × 20 cm, 500-2000 μm) were purchased from 
Merck. Proton (1H), carbon (13C), Fluorine (19F) and phosphorus (31P) NMR spectra were 
recorded on a Bruker Avance 500 MHz spectrometer at 25 °C. Spectra were autocalibrated to 
the deuterated solvent peak, and all 13C NMR and 31P NMR were proton decoupled. The purity 
of the final compounds was verified to be >95% by HPLC analysis using either i) 
ThermoSCIENTIFIC, SPECTRA SYSTEM P4000, detector SPECTRA SYSTEM UV2000, Varian 
Pursuit XRs 5 C18, 150 x 4.6 mm (as an analytic column) or ii) Varian Prostar (LC Workstation-
Varian Prostar 335 LC detector), Thermo SCIENTIFIC Hypersil Gold C18, 5 μm, 150 x 4.6 mm 
(as an analytical column) with a gradient elution of H2O/ CH3CN from 100/0 to 0/100 in 35 
min, flow = 1 mL/min, λ = 275 nm. Mass spectra were performed on Bruker Daltonics 
microTOF-LC, (atmospheric pressure ionisation, electron spray mass spectroscopy) in either 
positive or negative mode. 
2ʹ,3ʹ-Dideoxy-2ʹ,3ʹ-didehydrothymidine 5ʹ-(phenyl methoxyalaninyl phosphate) (5a) 
1H NMR (CDCl3): δ 8.80, 8.76 (2bs, 1H, NH), 7.36-7.13 (m, 6H, ArH, H-6), 7.05-6.99 (2m, 1H, H-
1ʹ), 6.37-6.26 (2dt, J = 6, 2 Hz, 1H, H-2ʹ), 5.93 -5.85 (2m, 1H, H-3ʹ), 5.06-4.98 (2m, 1H, H-
4ʹ), 4.42-4.26 (2m, 2H, H-5ʹ), 4.04-3.93 (m, 1H, Ala CH), 3.71, 3.70 (2s, 3H, OCH3), 2.00 (bs, 1H, 
NH), 1.86, 1.82 (2d, J = 0.3 Hz, 3H, CH3- 5), 1.36, 1.32 (2d, J = 7 Hz, 3H, Ala CH3); 31P NMR 
(CDCl3): δ 3.10, 2.49; 13C NMR (CDCl3): 173.96, 173.82 (2d, 3JC-P = 7.1 Hz, C=O ester), 163.69, 
163.63 (ArC-4), 150.79, 150.75 (C=O, C-2), 150.42, 150.28 (2d, 2JC-P = 6.3 Hz, ArC ipso phenyl), 
135.88, 135.61 (ArCH, C-6), 133.37, 132.07 (C-3’), 129.80, 129.74 (ArCH) ,127.49, 127.33 (C-
2’), 125.25, 125.19 (ArCH), 120.19, 120.05 (2d, 2JC-P = 3.8, 5 Hz, ArCH), 111.41, 111.29 (C-
5), 89.85, 89.62 (C-1ʹ), 84.71, 84.64 ( C-4ʹ), 67.16, 66.55 (2d, 2JC-P = 5, 3.8 Hz, C-5ʹ), 52.60, 
52.58 (OCH3), 50.21, 50.09 (AlaCH), 20.96, 20.90 (2d, 5 Hz, Ala CH3), 12.34, 12.30 (CH3, C-
5). MS (ES+) m/z: 488.1 (M+Na+), C20H24N3O8P, Reverse-phase HPLC, eluting with H2O/CH3CN 
from 90/10 to 0/100 in 30 min; ﬂow = 1 mL/min, tR = 15.00 min. yield 28%. 
2ʹ,3ʹ-Didehydro-2ʹ,3ʹ-dideoxythymidine 5ʹ-(3-trifluoromethylphenylmethoxyalaninyl 
phosphate) (5b)   
1H NMR (CDCl3): δ 9.24, 9.21 (2bs, 1H, NH), 7.49-7.38 (m, 4H, ArH), 7.29-7.20 (2m, 1H, H-
6), 7.05-7.00 (2m, 1H, H-1ʹ), 6.36-6.27 (2dt, J = 6, 2 Hz, 1H, H-2ʹ), 5.94 -5.87 (2m, 1H, H-
3’), 5.07-4.99 (2m, 1H, H-4ʹ), 4.43-4.24 (2m, 2H, H-5ʹ), 4.11-3.94 (m, 2H, Ala CH, NH), 3.71, 
3.70 (2s, 3H, OCH3), 1.86, 1.81 (2d, J = 1.5 Hz, 3H, CH3- 5), 1.38, 1.35 (2d, J = 7 Hz, 3H, Ala 
CH3); 31P NMR (CDCl3): δ 3.25, 2.63; 19F NMR (CDCl3): δ -62.74, -62.75; 13C NMR 
(CDCl3): 173.90, 173.74 (2d, 3JC-P = 7.5 Hz, C=O ester), 163.83, 163.79 (ArC-4), 150.86 ( C=O, C-
2), 150.63, 150.50 (2d, 2JC-P = 6.3, 5 Hz, ArC ipso phenyl), 135.68, 135.48 (ArCH, C-6), 133.09, 
132.83 (C-3’), 130.47 (ArCH) , 130.06 (m, ArC), 127.68, 127.58 (C-2’), 123.85, 123.68 (2d, 2JC-
P = 3.8, 5 Hz, ArCH), 123.39 (q, 1JC-P = 270.8 Hz, CF3), 121.96 (m, ArCH), 117.39 (m, ArCH), 
111.44, 111.27 (C-5), 89.92, 89.65 (C-1ʹ), 84.54, 84.51 (2d, 2JC-P = 3.8, 5 Hz, C-4ʹ), 67.47, 
66.80 (2d, 2JC-P = 3.8, 5 Hz, C-5ʹ), 52.64 (OCH3), 50.24, 50.13 (AlaCH), 20.89, 20.80 (2d, 5. 
6.3 Hz, Ala CH3), 12.34, 12.26 (CH3, C-5).  MS (ES+) m/z: 556.1 
(M+Na+), C21H23F3N3O8P, Reverse-phase HPLC, eluting with H2O/CH3CN from 90/10 to 0/100 
in 30 min; ﬂow = 1 mL/min, tR = 14.97 min. yield 20%. 
 2ʹ,3ʹ-Didehydro-2ʹ,3ʹ-dideoxythymidine-5ʹ(4-(trifluoromethyl)phenyl methoxy alaninyl 
phosphate) (5c). 
1H NMR (CDCl3): δ 8.49, 8.45 (2bs, 1H, NH), 7.54 (d, J = 8 Hz, 2H, ArH), 7.26, 7.23 (d, J = 8.5, 
9 Hz, 2H, ArH), 7.21-7.13 (2m, 1H, H-6), 6.98-6.93 (2m, 1H, H-1ʹ), 6.31-6.21 (2dt, J = 6, 2 Hz, 
1H, H-2’), 5.88 -5.82 (2m, 1H, H-3’), 5.01-4.93 (2m, 1H, H-4ʹ), 4.35-4.16 (2m, 2H, H-5ʹ), 3.98-
3.86 (m, 1H, Ala CH), 3.76-3.66 (m, 1H, NH), 3.64, 3.63 (2s, 3H, OCH3), 1.81, 1.76 (2d, J = 1 Hz, 
3H, CH3- 5), 1.31, 1.27 (2d, J = 7 Hz, 3H, Ala CH3); 31P NMR (CDCl3): δ 2.95, 2.41; 19F NMR 
(CDCl3): δ -62.21, -62.22; 13C NMR (CDCl3): 173.74, 173.60 (C=O ester), 163.44, 163.41 (ArC-
4), 153.04, 152.84 (ArC ipso phenyl), 150.62 ( C=O, C-2), 135.68, 135.46 (ArCH, C-6), 133.18, 
132.87 (C-3ʹ),  127.70, 127.55 (C-2ʹ), 127.21 (m, ArCH), 124.83 (ArC), 122.93 (ArC), 120.49 
(2d, J = 5 Hz,, ArCH), 111.42, 111.27 (C-5), 89.96, 89.71 (C-1ʹ), 84.54, 84.47 (C-4ʹ), 67.49, 66.80 
(2d, 2JC-P = 3.8, 5 Hz, C-5ʹ), 52.69 (OCH3), 50.21,50.14 (AlaCH), 20.98, 20.90 (2d, 5 Hz, Ala 
CH3), 12.39, 12.36 (CH3, C-5). MS (ES+) m/z: 556.1 (M+Na+), C21H23F3N3O8P, Reverse-phase 
HPLC, eluting with H2O/CH3CN from 90/10 to 0/100 in 30 min; ﬂow = 1 mL/min, tR = 
17.08 min. yield 24%. 
 2ʹ,3ʹ-Didehydro-2ʹ,3ʹ-dideoxythymidine-5ʹ-(3-(pentafluorosulfanyl)phenyl methoxy 
alaninyl phosphate) (5d) 
1H NMR (CDCl3): δ 9.11 (bs, 1H, NH), 7.54-7.49 (m, 2H, ArH), 7.41-7.31 (m, 2H, ArH), 7.21-
7.11 (2m, 1H, H-6), 6.97-6.93 (2m, 1H, H-1ʹ), 6.28-6.20 (2m, 1H, H-2ʹ), 5.88 -5.82 (2m, 1H, H-
3ʹ), 5.00-4.92 (2m, 1H, H-4ʹ), 4.35-4.17 (2m, 2H, H-5ʹ), 3.98-3.88 (m, 1H, Ala CH), 3.64, 
3.64 (2s, 3H, OCH3), 1.82 (bs, 1H, NH), 1.78, 1.74 (2d, J = 1 Hz, 3H, CH3- 5), 1.32, 1.27 (2d, J = 
6.5 Hz, 3H, Ala CH3); 31P NMR (CDCl3): δ 3.10, 2.60; 19F NMR (CDCl3): δ 83.21 (p, J = 149.9 Hz, 
1F), 62.82, 62.80 (2d, J = 149.9, 150.4 Hz, 4F); 13C NMR (CDCl3): 173.88, 173.66 (2d, 3JC-P = 6.5, 
7.4 Hz, C=O ester), 163.68, 163.63 (ArC, C-4), 154.41 (m, ArC, CSF5), 150.76 ( C=O, C-
2), 150.18, 150.04 (2d, 2JC-P = 5.8 Hz, ArC ipso phenyl), 135.64, 135.44 (ArCH, C-6), 133.05, 
132.77 (C-3ʹ), 129.91 (ArCH) ,127.73, 127.63 (C-2ʹ), 123.80, 123.60 (2d, 2JC-P = 3.8, 
5 Hz, ArCH), 122.66 (m, ArCH), 118.55 (m, ArCH), 111.45, 111.27 (ArC, C-5), 89.96, 89.68 (C-
1ʹ), 84.48, 84.42 (2d, 3JC-P = 2.5 Hz, C-4ʹ), 67.58, 66.86 (2d, 2JC-P = 4, 3.8 Hz, C-5ʹ), 52.69 
(OCH3), 50.25, 50.16 (Ala CH), 20.93, 20.82 (2d, 5, 6.3 Hz, Ala CH3), 12.35, 12.25 (CH3, C-5).  
MS (ES+) m/z: 614.1 (M+Na+), C20H23F5N3O8PS, Reverse-phase HPLC, eluting with H2O/CH3CN 
from 90/10 to 0/100 in 30 min; ﬂow = 1 mL/min, tR = 16.01 min. yield 34%. 
S2. Carboxypeptidase Y enzymatic assay procedure 
The enzymatic activation of the protides towards carboxypeptidase Y was studied using in situ 
31P NMR. The experiment was carried out by dissolving 5d (5.0 mg) in d6-acetone (0.15 mL) 
and adding Trizma buffer pH 7.6 (0.30 mL). The resulting solution was placed in an NMR tube 
and a 31P NMR experiment at 25 °C was recorded as the blank experiment. The enzyme 
carboxypeptidase Y (0.1 mg) was dissolved in Trizma (0.15 mL) and added to the solution of 
the phosphoramidate derivative in the NMR tube. The 31P-NMR experiment was performed 
recording the experiment every 7 min at 25 °C. 
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PL2W        14.33185768 W
PL13             120.00 dB
PL12              14.85 dB
PL2               −2.00 dB
PCPD2             80.00 usec
NUC2                 1H
CPDPRG2         waltz16
======== CHANNEL f2 ========
SFO1        202.4563350 MHz
PL1W        24.34000015 W
PL1                4.00 dB
P1                10.40 usec
NUC1                31P
======== CHANNEL f1 ========
TD0                   1
D11          0.03000000 sec
D1           1.65999997 sec
TE                298.1 K
DE                12.00 usec
DW               61.867 usec
RG                 3250
AQ            1.0136734 sec
FIDRES         0.493280 Hz
SWH            8081.896 Hz
DS                    4
NS                   16
SOLVENT           CDCl3
TD                16384
PULPROG          zgpg30
PROBHD   5 mm QNP 1H/13
INSTRUM       Avance500
Time              11.27
Date_          20140721
PROCNO                1
EXPNO                 5
NAME         CM−SK73Vir
19F NMR spectrum of ProTide (5c) 
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PC                 1.40
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          470.5923770 MHz
SI                65536
SFO2        500.1320005 MHz
PL12W        0.29600734 W
PL2W        14.33185768 W
PL12              14.85 dB
PL2               −2.00 dB
PCPD2             80.00 usec
NUC2                 1H
CPDPRG2         waltz16
======== CHANNEL f2 ========
SFO1        470.5453180 MHz
PL1W        11.14113998 W
PL1               −1.50 dB
P1                18.60 usec
NUC1                19F
======== CHANNEL f1 ========
TD0                   1
D12          0.00002000 sec
D11          0.03000000 sec
D1           1.00000000 sec
TE                298.1 K
DE                 6.00 usec
DW                4.400 usec
RG                 2580
AQ            0.5767668 sec
FIDRES         0.866977 Hz
SWH          113636.367 Hz
DS                    4
NS                   16
SOLVENT           CDCl3
TD               131072
PULPROG        zgfhigqn
PROBHD   5 mm QNP 1H/13
INSTRUM       Avance500
Time              11.43
Date_          20140721
PROCNO                1
EXPNO                 6
NAME         CM−SK73Vir
13C NMR spectrum of ProTide (5c) 
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PC                 1.40
GB                    0
LB                 1.00 Hz
SSB                   0
WDW                  EM
SF          125.7577890 MHz
SI                32768
SFO2        500.1320005 MHz
PL12W        0.29600734 W
PL2W        14.33185768 W
PL12              14.85 dB
PL2               −2.00 dB
PCPD2             80.00 usec
P4                23.00 usec
P3                11.50 usec
NUC2                 1H
CPDPRG2         waltz16
======== CHANNEL f2 ========
SFO1        125.7703643 MHz
PL1W       101.27846527 W
PL1               −2.00 dB
P2                14.40 usec
P1                 7.20 usec
NUC1                13C
======== CHANNEL f1 ========
TD0                   2
D20          0.00345000 sec
D15          0.00431034 sec
D12          0.00002000 sec
D4           0.00172414 sec
D1           2.00000000 sec
CNST2       145.0000000
TE                298.1 K
DE                12.00 usec
DW               16.800 usec
RG                 3250
AQ            1.1010548 sec
FIDRES         0.454131 Hz
SWH           29761.904 Hz
DS                    4
NS                  256
SOLVENT           CDCl3
TD                65536
PULPROG         pendant
PROBHD   5 mm QNP 1H/13
INSTRUM       Avance500
Time              10.53
Date_          20140810
PROCNO                1
EXPNO                 9
NAME         CM−SK73Vir
HPLC analysis spectrum of ProTide 5c  
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SK73Vir2.DATA - Prostar 335 Absorbance Analog Channel 1 EL04099020          
Min
35343332313029282726252423222120191817161514131211109876543210
m
AU
3,600
3,400
3,200
3,000
2,800
2,600
2,400
2,200
2,000
1,800
1,600
1,400
1,200
1,000
800
600
400
200
0
SP
W
 0
.2
0
ST
H 
10
.0
0
Peak results :
Index
1
2
3
4
5
6
7
Total
Name
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
Time
[Min]
2.36
2.55
2.91
3.20
13.07
14.97
25.60
Quantity
[% Area]
0.07
0.05
0.02
0.01
0.03
99.72
0.11
100.00
Height
[mAU]
11.6
3.0
1.9
0.9
2.0
3491.3
6.3
3517.0
Area
[mAU.Min]
0.5
0.4
0.1
0.1
0.2
810.1
0.9
812.3
Area %
[%]
0.066
0.050
0.018
0.009
0.028
99.721
0.107
100.000
1H NMR spectrum of ProTide (5d) 
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PC                 1.00
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          500.1300070 MHz
SI                32768
SFO1        500.1330885 MHz
PL1W        11.38419914 W
PL1               −1.00 dB
P1                11.50 usec
NUC1                 1H
======== CHANNEL f1 ========
TD0                   1
D1           1.00000000 sec
TE                298.1 K
DE                 6.50 usec
DW               48.400 usec
RG                  228
AQ            3.1719923 sec
FIDRES         0.157632 Hz
SWH           10330.578 Hz
DS                    2
NS                   16
SOLVENT           CDCl3
TD                65536
PULPROG            zg30
PROBHD   5 mm QNP 1H/13
INSTRUM       Avance500
Time              21.50
Date_          20140715
PROCNO                1
EXPNO                16
NAME         CM−SK57Vir
1213141516 ppm
31P NMR spectrum of ProTide (5d) 
−15−10−515 10 5 0 ppm
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PC                 1.40
GB                    0
LB                 1.00 Hz
SSB                   0
WDW                  EM
SF          202.4563350 MHz
SI                32768
SFO2        500.1320005 MHz
PL13W        0.00000000 W
PL12W        0.29600734 W
PL2W        14.33185768 W
PL13             120.00 dB
PL12              14.85 dB
PL2               −2.00 dB
PCPD2             80.00 usec
NUC2                 1H
CPDPRG2         waltz16
======== CHANNEL f2 ========
SFO1        202.4563350 MHz
PL1W        24.34000015 W
PL1                4.00 dB
P1                10.40 usec
NUC1                31P
======== CHANNEL f1 ========
TD0                   1
D11          0.03000000 sec
D1           1.65999997 sec
TE                298.1 K
DE                12.00 usec
DW               61.867 usec
RG                 3250
AQ            1.0136734 sec
FIDRES         0.493280 Hz
SWH            8081.896 Hz
DS                    4
NS                   16
SOLVENT           CDCl3
TD                16384
PULPROG          zgpg30
PROBHD   5 mm QNP 1H/13
INSTRUM       Avance500
Time              13.13
Date_          20140703
PROCNO                1
EXPNO                12
NAME         CM−SK57Vir
19F NMR spectrum of ProTide (5d) 
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PC                 1.40
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          470.5923770 MHz
SI                65536
SFO2        500.1320005 MHz
PL12W        0.29600734 W
PL2W        14.33185768 W
PL12              14.85 dB
PL2               −2.00 dB
PCPD2             80.00 usec
NUC2                 1H
CPDPRG2         waltz16
======== CHANNEL f2 ========
SFO1        470.5923770 MHz
PL1W        11.14113998 W
PL1               −1.50 dB
P1                18.60 usec
NUC1                19F
======== CHANNEL f1 ========
TD0                   1
D12          0.00002000 sec
D11          0.03000000 sec
D1           1.00000000 sec
TE                298.1 K
DE                 6.00 usec
DW                3.600 usec
RG                 2300
AQ            0.4719092 sec
FIDRES         1.059638 Hz
SWH          138888.891 Hz
DS                    4
NS                   16
SOLVENT           CDCl3
TD               131072
PULPROG        zgfhigqn
PROBHD   5 mm QNP 1H/13
INSTRUM       Avance500
Time              13.14
Date_          20140703
PROCNO                1
EXPNO                13
NAME         CM−SK57Vir
13C NMR spectrum of ProTide (5d) 
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PC                 1.40
GB                    0
LB                 1.00 Hz
SSB                   0
WDW                  EM
SF          125.7577890 MHz
SI                32768
SFO2        500.1320005 MHz
PL12W        0.29600734 W
PL2W        14.33185768 W
PL12              14.85 dB
PL2               −2.00 dB
PCPD2             80.00 usec
P4                23.00 usec
P3                11.50 usec
NUC2                 1H
CPDPRG2         waltz16
======== CHANNEL f2 ========
SFO1        125.7703643 MHz
PL1W       101.27846527 W
PL1               −2.00 dB
P2                14.40 usec
P1                 7.20 usec
NUC1                13C
======== CHANNEL f1 ========
TD0                   8
D20          0.00345000 sec
D15          0.00431034 sec
D12          0.00002000 sec
D4           0.00172414 sec
D1           2.00000000 sec
CNST2       145.0000000
TE                298.1 K
DE                12.00 usec
DW               16.800 usec
RG                 3250
AQ            1.1010548 sec
FIDRES         0.454131 Hz
SWH           29761.904 Hz
DS                    4
NS                 1024
SOLVENT           CDCl3
TD                65536
PULPROG         pendant
PROBHD   5 mm QNP 1H/13
INSTRUM       Avance500
Time              21.02
Date_          20140715
PROCNO                1
EXPNO                15
NAME         CM−SK57Vir
HPLC analysis spectrum of ProTide 5d 
 
Chromatogram : SK57Vir2_channel1
System : HPLC_Analytical
Method : 5FU-Blanka ACN 30+5min ok
User : User1
Acquisition time: 7/21/2014 11:59:40 AM
DAte: 7/21/2014
Time: 12:57:36 PM
Acquired : 7/21/2014 11:59:40 AM
Processed  : 7/21/2014 12:57:23 PM
Printed : 7/21/2014 12:57:36 PM
Method: 5FU-Blanka ACN 30+5min ok
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SK57Vir2.DATA - Prostar 335 Absorbance Analog Channel 1 EL04099020          
Min
35343332313029282726252423222120191817161514131211109876543210
m
AU
120
115
110
105
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
-5
SP
W
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Peak results :
Index
3
1
2
Total
Name
UNKNOWN
UNKNOWN
UNKNOWN
Time
[Min]
15.16
16.01
25.81
Quantity
[% Area]
2.06
97.15
0.80
100.00
Height
[mAU]
2.9
102.0
2.1
107.1
Area
[mAU.Min]
0.5
24.2
0.2
24.9
Area %
[%]
2.055
97.145
0.800
100.000
